Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04141020 · ClinicalTrials.gov registry record · Phase 2
Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms
A Phase 2 study of Cerebral Aneurysm, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04141020 is a Phase 2 study of Cerebral Aneurysm that is actively recruiting participants, run by University of Miami. The registered enrollment target is 80 participants, above the 50-participant average among 3 other Cerebral Aneurysm trials with a reported enrollment target (60% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04141020, a Phase 2 study of Cerebral Aneurysm, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.
Conditions Studied
Interventions
- DRUG Sirolimus
- PROCEDURE Microsurgical clipping
- PROCEDURE Endovascular treatment
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-10-27 |
| Est. Completion | 2026-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04141020
The ClinicalTrials.gov registry entry for NCT04141020 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 50-participant average among 3 other Cerebral Aneurysm trials with a reported enrollment target (60% higher). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cerebral Aneurysm appearing as the primary indexed condition, and to 3 interventions - of which Sirolimus is the first listed.
NCT04141020 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT04141020 about?
NCT04141020 is a clinical study titled "Effect of Sirolimus on Molecular Alterations in Cerebral Aneurysms". The objective of this study is to explore the effects of Sirolimus on the underlying molecular alterations of cerebral aneurysms.
What is the current status of trial NCT04141020?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-10-27. Estimated completion is 2026-11-01.
What conditions does trial NCT04141020 study?
This clinical trial studies the following conditions: Cerebral Aneurysm.
What interventions are being tested in trial NCT04141020?
The interventions under investigation include: Sirolimus (DRUG), Microsurgical clipping (PROCEDURE), Endovascular treatment (PROCEDURE).
Who is sponsoring clinical trial NCT04141020?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04141020 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cerebral Aneurysm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.